TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25818103
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention (diet, smoking cessation, and exercise) with oral and written information provided in a booklet for postoperative rehabilitation.
Study: 23864581
Drug: Metformin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin monotherapy (more than 360 defined daily doses)
Study: 23864581
Drug: Antidiabetic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidiabetic drugs other than metformin
Study: 10365640
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg/d for 1 week
Study: 9816035
Drug: Amonafide at
Normalized name: amonafide
DrugBank: Amonafide (DB05022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amonafide at 300 mg/m2/day i.v. for 5 days, repeated at 21-day intervals for a maximum of four cycles.
Study: 7003611
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg DT gamma E (intra-muscular injections for 4 days)
Study: 28242714
Drug: Time-averaged on-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-averaged on-treatment SBP at 120 to 130 mm Hg (mean, 126.2 mm Hg)
Study: 28242714
Drug: Time-averaged on-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-averaged on-treatment SBP at 130 to 135 mm Hg (mean, 132.6 mm Hg)
Study: 28242714
Drug: Time-averaged on-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-averaged on-treatment SBP at 135 to 140 mm Hg (mean, 137.5 mm Hg)
Study: 28242714
Drug: Time-averaged on-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-averaged on-treatment SBP <120 mm Hg (mean, 116.7 mm Hg)
Study: 8341998
Drug: Six-month therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six-month therapy with daily Rifater for two months, followed by isoniazid and rifampicin for four months (n = 128)
Study: 8341998
Drug: Initial drug
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial drug resistance to isoniazid
Study: 8341998
Drug: Subsequent multi-drug
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent multi-drug therapy
Study: 31113475
Drug: Antibiotics at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics at home
Study: 25839406
Drug: ombitasvir/paritaprevir/ritonavir (25mg/150mg/100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ombitasvir/paritaprevir/ritonavir (25mg/150mg/100mg once daily) and dasabuvir (250mg twice daily) + weight-based ribavirin for 12 weeks
Study: 24067081
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline (23 ml/kg)
Study: 24067081
Drug: 5% glucose
Normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glucose (23 ml/kg)
Study: 17182222
Drug: Monthly booster
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly booster sessions for a further nine months
Study: 12235221
Drug: Two-drug combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-drug combinations containing at least one new agent
Study: 16163169
Drug: Newer targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer targeted therapies
Study: 9555615
Drug: Cetirizine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine treatment for one week
Study: 7480963
Drug: r-alpha-IFN-2a (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-alpha-IFN-2a (3 MU thrice weekly for 12 months)
Study: 7480963
Drug: r-alpha-IFN-2b (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-alpha-IFN-2b (3 MU thrice weekly for 12 months)
Study: 31735634
Drug: Ranibizumab (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (0.5 mg and 2.0 mg) administered monthly or on an as-needed basis (PRN)
Study: 29265836
Drug: Compassion-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compassion-focused therapy (CFT) as guided self-help
Study: 1276560
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (placebo treatment)
Study: 23885649
Drug: Delayed surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed surgery (>5 days) for patients on antiplatelet therapy
Study: 23885649
Drug: Early surgery
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early surgery (<48 h) for patients not on antiplatelet therapy
Study: 11700577
Drug: Tafenoquine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine 400 mg for 3 days followed by placebo weekly
Study: 7944932
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human interferon gamma, 100 micrograms, administered subcutaneously once daily for 21 days (or until patient discharge if prior to 21 days)
Study: 23420574
Drug: 400 ml
Normalized name: Lantidra 400 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 ml beer (4.7% vol)
Study: 23420574
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml red wine (13.7% vol)
Study: 23420574
Drug: Whisky and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whisky and high proof ethanol solution
Study: 12731402
Drug: Magnetostimulation (Viofor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetostimulation (Viofor JPS system; M2P2 program; induction‐‐25‐80 microT; frequency‐‐200 Hz, complex saw‐like shape) applied for 12 min daily, repeated 15 times
Study: 10431577
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy followed by hematopoietic stem cell transplant
Study: 7742127
Drug: Contrast-enhanced MR
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast-enhanced MR imaging using high dose (0.3 mmol/kg b.w.) Gadodiamide injection
Study: 7742127
Drug: Contrast-enhanced MR
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast-enhanced MR imaging using standard dose (0.1 mmol/kg b.w.) Gadodiamide injection
Study: 1952841
Drug: Rimantadine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimantadine (10 days treatment)
Study: 1952841
Drug: Rimantadine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimantadine (5 days treatment)
Study: 6452790
Drug: Zimelidine (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimelidine (selective serotonin‐uptake inhibitor)
Study: 10674508
Drug: rapacuronium 2
Normalized name: rapacuronium 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: rapacuronium 2 mg x kg(‐1)
Study: 8554083
Drug: Higher, conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher, conventional dose of levodopa and carbidopa
Study: 6285445
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg, 3 times daily)
Study: 2113764
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg, 3 times daily)
Study: 30845731
Drug: Combined supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined supplementation with glycine (3.0 g) and tryptophan (0.2 g)
Study: 27266506
Drug: Auricular point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular point acupressure (APP) treatment using vaccaria seeds on the large intestine point (CO7)
Study: 21883559
Drug: Biomechanical preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomechanical preparation
Study: 18004131
Drug: Ethanol (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.7 g/kg)
Study: 9802364
Drug: Fel d
Normalized name: Anti-cat allergen fel d 1 monoclonal anitbody regn-1908
DrugBank: Freneslerbart (DB19080)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fel d 1 peptides (high dose, 750 micro(g))
Study: 9802364
Drug: Fel d
Normalized name: Anti-cat allergen fel d 1 monoclonal anitbody regn-1908
DrugBank: Freneslerbart (DB19080)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fel d 1 peptides (medium dose, 75 micro(g))
Study: 9802364
Drug: Fel d
Normalized name: Anti-cat allergen fel d 1 monoclonal anitbody regn-1908
DrugBank: Freneslerbart (DB19080)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fel d 1 peptides (low dose, 7.5 micro(g))
Study: 26491117
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (9 mg elemental zinc daily for 4 weeks)
Study: 26491117
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical tablet for 4 weeks)
Study: 24036613
Drug: Intraoperative periarticular
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative periarticular infiltration with ropivacaine, clonidine, morphine, epinephrine and corticosteroids
Study: 8424508
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia (PCA) with morphine
Study: 24036613
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion with ropivacaine
Study: 15312558
Drug: Oseltamivir (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir (75 mg, twice daily for 5 days)
Study: 11224816
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of BSA and resistance exercise (SAR)
Study: 22344198
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate depot (both doses)
Study: 20631016
Drug: Decrease in
Normalized name: Titanium Dioxide 7.2 g in 100 mL / Zinc Oxide 4 g in 100 mL TOPICAL LIQUID [Decree Daily Shield Broad Spectrum SPF 30 Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decrease in insulin sensitivity (1 mg x kg(‐1) x min(‐1))
Study: 2180105
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone 40 mg per day for two weeks
Study: 6110436
Drug: Isoprenaline 10
Normalized name: Isoprénaline
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoprenaline 10 or 20 mg sublingually 30 min before the meal
Study: 6110436
Drug: Salbutamol 4
Normalized name: Salbutamol 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 4 mg four times daily for 1 week
Study: 6110436
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg four times daily for 1 week (after isoprenaline)
Study: 29541927
Drug: Treatment preference
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment preference (preferred vs non-preferred)
Study: 29541927
Drug: Pharmacotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy with sertraline (SER)
Study: 26514581
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral THC
Study: 10211146
Drug: Olanzapine (5‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5‐20 mg)
Study: 10211146
Drug: Haloperidol (5‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (5‐20 mg)
Study: 2196085
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CyA) at 2.5 mg/kg/day
Study: 2196085
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CyA) at 5 mg/kg/day
Study: 19337010
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin aspart 30 (BIAsp30) + metformin (met)
Study: 19337010
Drug: Premixed human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premixed human insulin 30/70 (BHI30) + metformin (met)
Study: 11440285
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg/d
Study: 17261662
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg/d (in patients without a history of HF)
Study: 15289727
Drug: Low-dose daily
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose daily chemotherapy (50 mg carboplatin and 50 mg etoposide)
Study: 15289727
Drug: High-dose hyperfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose hyperfractionated radiation therapy (69.6 Gy) with concurrent chemotherapy
Study: 15289727
Drug: Weekend chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekend chemotherapy group
Study: 8306241
Drug: I.M. clonazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.M. clonazepam (1 to 2 mg)
Study: 3102056
Drug: melphalan (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: melphalan (8 mg/m2 orally for 4 days)
Study: 3102056
Drug: melphalan (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: melphalan (6 mg/m2 for 4 days) and hexamethylmelamine (120 mg/m2 for 14 days) every 4 weeks
Study: 24811085
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (630 nm, 28 mW, continuous wave, 60 s, 1.68 J)
Study: 21496138
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV acetaminophen 1 g
Study: 21496138
Drug: PO acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO acetaminophen 1 g
Study: 25521843
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV acetaminophen
Study: 27839957
Drug: PO acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO acetaminophen
Study: 16316746
Drug: Acetyl-L-carnitine (ALCAR)
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine (ALCAR)
Study: 16316746
Drug: Acetyl-L-carnitine (ALCAR)
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine (ALCAR) and Amisulpride
Study: 10848901
Drug: Intranasal mometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal mometasone furoate 200 microgram
Study: 10848901
Drug: Oral montelukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral montelukast 10 mg
Study: 8798046
Drug: Ioxaglate (Hexabrix);
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ioxaglate (Hexabrix); 320 mg I/ml, injected at 2 ml/kg b.w. (max 100 ml)
Study: 920841
Drug: 250 mg/day
Normalized name: alpelisib 250 mg/day (200 mg x 1 and 50 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/day of disulfiram
Study: 920841
Drug: 500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day of disulfiram
Study: 20401662
Drug: B vitamins
Normalized name: B-50 Hi Potency B Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: B vitamins alone (1 mg folic acid, 7.2 mg pyridoxine, 0.02 mg cyanocobalamin daily)
Study: 20401662
Drug: Antioxidants alone
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidants alone (150 mg ascorbic acid, 67 mg vitamin E, 9 mg β-carotene daily)
Study: 15979810
Drug: Low-dose alcohol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose alcohol infusion (0.2 g/kg)
Study: 31374985
Drug: SUCROSE (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUCROSE (50 g sucrose)
Study: 31374985
Drug: MALT (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: MALT (120 mg sucralose matched with 50 g maltodextrin)
Study: 31374985
Drug: NNS (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNS (120 mg sucralose)
Study: 29339723
Drug: fasoracetam (NFC-1)
Normalized name: Fasoracetam
DrugBank: Fasoracetam (DB16163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fasoracetam (NFC-1) 400 mg BID for 4 weeks
Study: 21802266
Drug: High-mucilage dose
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-mucilage dose (HM)
Study: 21802266
Drug: Low-mucilage dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-mucilage dose (LM)
Study: 2236453
Drug: Fluoxetine 60
Normalized name: fluoxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 60 mg/day
Study: 1331830
Drug: Granisetron 40
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron 40 micrograms/kg i.v. given once prior to chemotherapy
Study: 1331830
Drug: Granisetron 160
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron 160 micrograms/kg i.v. given once prior to chemotherapy
Study: 8383688
Drug: Granisetron (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (both doses)
Study: 4028771
Drug: Daily dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dressing changes every 24 hours
Study: 24737912
Drug: Golimumab 50
Normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab 50 mg
Study: 25763862
Drug: Golimumab 100
Normalized name: golimumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab 100 mg
Study: 26471830
Drug: Golimumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab (both doses)
Study: 18557690
Drug: Present-centered group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Present-centered group therapy
Study: 7729281
Drug: Mesalamine 4
Normalized name: mesalamine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine 4 g/day
Study: 7729281
Drug: Mesalamine 1
Normalized name: mesalamine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine 1 g/day
Study: 7729281
Drug: Mesalamine 2
Normalized name: mesalamine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine 2 g/day
Study: 6452833
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of DSCG and IPTB
Study: 26627879
Drug: Enoxaparin/warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin/warfarin
Study: 31415780
Drug: Nonsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical treatment for stress urinary incontinence
Study: 28262140
Drug: Medication only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication only condition (Control)
Study: 26468123
Drug: Selenate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenate (400 μg/d)
Study: 21877766
Drug: JP formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: JP formulation of pitavastatin 2 mg
Study: 21877766
Drug: EU formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: EU formulation of pitavastatin 2 mg
Study: 17479142
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in stroke units
Study: 17479142
Drug: Combined stroke
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined stroke units (offering both acute medical treatment and rehabilitation)
Study: 9710685
Drug: pravastatin (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: pravastatin (20-40 mg)
Study: 7991936
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus glipizide (3 x 10 mg/day)
Study: 8877026
Drug: Ketoconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (200 mg)
Study: 2499150
Drug: Terbinafine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine (500 mg)
Study: 25326831
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both supplements (PLX(®) and almond beverage)
Study: 23281041
Drug: Add teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Add teriparatide 20 µg/day
Study: 23281041
Drug: Switch to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to teriparatide 20 µg/day
Study: 18431541
Drug: Standard physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physical therapy (hot pack, ultrasound therapy, exercise program)
Study: 18431541
Drug: Traction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traction therapy in addition to standard physical therapy
Study: 16842389
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg rac-albuterol
Study: 1666179
Drug: HOE 427
Normalized name: CASTOR OIL 3 mg in 30 mg / ROSEMARY 4.5 mg in 30 mg / TOCOPHEROL 9 mg in 30 mg TOPICAL LIQUID [HOEGOA Herbal Hair Growth OiI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOE 427 (ebiratide), administered intravenously in a pulsatile mode 4 times (120 micrograms each) at 2200, 2300, 2400 and 0100
Study: 7066127
Drug: Buprenorphine 0.1
Normalized name: buprenorphine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.1 or 0.2 mg i.v. on patient demand using the 'Cardiff' palliator
Study: 21078941
Drug: Quinine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine treatment
Study: 17431728
Drug: Spa therapy
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa therapy (n = 10) - 10-day course including thermal pool baths at 37 degrees C for 20 min two times daily
Study: 23989945
Drug: Home treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home treatment
Study: 22405255
Drug: Misoprostol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (200 μg vaginally, 2 tablets, 3 hours before abortion)
Study: 19413507
Drug: Four‐Agents‐Decoction (Si
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four‐Agents‐Decoction (Si Wu Tang)
Study: 15552635
Drug: Morning dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dosing of 1000 mg extended-release divalproex sodium